reports
Immunogen Inc: 2 directors
Two Directors at Immunogen Inc sold after exercising options/sold 239,062 shares at between 15.290USD and 16.660USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
- Dave Nicoski
- Ross LaDuke
BAC BANK OF AMERICA CORP
WEN WENDY'S COMPANY
URBN URBAN OUTFITTERS INC.
TLYS TILLYS
TJX TJX COMPANIES INC
RNST RENASANT CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
M MACY'S INC
LOCO EL POLLO LOCO HOLDINGS INC
IMGN IMMUNOGEN INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
GPS GAP INC.
FBNC FIRST BANCORP (NORTH CAROLINA)
DKS DICK'S SPORTING GOODS INC.
CROX CROCS INC.
CHUY CHUY'S HOLDINGS INC.
CHH CHOICE HOTELS INTERNATIONAL INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BKE BUCKLE INC.
AVXL ANAVEX LIFE SCIENCES
ANIK ANIKA THERAPEUTICS INC.
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
CASS CASS INFORMATION SYSTEMS INC.
FHB FIRST HAWAIIAN INC.
PUMP PROPETRO HOLDING CORP.
BHF BRIGHTHOUSE FINANCIAL INC.
DNLI DENALI THERAPEUTICS INC
INVA INNOVIVA INC.
OZK BANK OZK
ALVR ALLOVIR
IMVT IMMUNOVANT
TSCO TESCO PLC
CADE BANCORPSOUTH BANK
VSCO VICTORIA'S SECRET & CO
IBRX IMMUNITYBIO INC
PRI COX COMMUNICATIONS
INC.
IMMUNOGEN sees an upgrade to Slightly Positive due to a better fundame...
The general evaluation of IMMUNOGEN (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was USD 5.26...
- Dave Nicoski
- Ross LaDuke
PHM PULTEGROUP INC.
VRTX VERTEX PHARMACEUTICALS INCORPORATED
MKC MCCORMICK & COMPANY INCORPORATED
LGIH LGI HOMES INC.
IMGN IMMUNOGEN INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
ASTE ASTEC INDUSTRIES INC.
UVE UNIVERSAL INSURANCE HOLDINGS INC.
CHRW C.H. ROBINSON WORLDWIDE INC.
TCDA TRICIDA
GOSS GOSSAMER BIO
ACET ADICET BIO INC
CCMP CMC MATERIALS INC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
Key Points: The Consumer Discretionary Sector continues to have several names as leadership. (ex. NWHM, DLA, DDS, DLTH, LAZY, and BGFV) Biotechnology has several leadership names. (ex. ALDX, CRSP, ANAB, NTLA, IMGN, DCPH, RAPT, IOVA, CBAY, EIDX, RTRX, CLPT, KALV, and SAGE)
SXT SENSIENT TECHNOLOGIES CORPORATION
STRL STERLING CONSTRUCTION COMPANY INC.
SAGE SAGE THERAPEUTICS INC.
RTRX TRAVERE THERAPEUTICS INC.
RBCAA REPUBLIC BANCORP INC. (KENTUCKY) CL A
FPR ALTO INGREDIENTS INC
IMGN IMMUNOGEN INC.
GOGO GOGO INC.
DDS DILLARD'S INC. CLASS A
CIT CIT GROUP INC.
CBAY CYMABAY THERAPEUTICS INC.
BMI BADGER METER INC.
BGFV BIG 5 SPORTING GOODS CORP.
ALDX ALDEYRA THERAPEUTICS
FLEXN FLEX LTD.
COWN COWEN INC CLASS A
NWHM NEW HOME CO. INC.
GV GENOMIC VISION SA
DLA DELTA APPAREL CO.
DLTH DULUTH HOLDINGS INC. CLASS B
KALU KAISER ALUMINUM CORPORATION
KELYA KELLY SERVICES INC. CLASS A
NC NACCO INDUSTRIES INC. CL A
X UNITED STATES STEEL CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
AXON AXON ENTERPRISE INC
ANAB ANAPTYSBIO INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
IOVA IOVANCE BIOTHERAPEUTICS INC
HBB HAMILTON BEACH BRANDS HOLDING COMPANY
CATC CAMBRIDGE BANCORP
DCPH DECIPHERA PHARMACEUTICALS INC.
WRK WESTROCK COMPANY
IEA INFRASTRUCTURE AND ENERGY ALTERNATIVES
LAZY LAZYDAYS HOLDINGS
GSHD GOOSEHEAD INSURANCE
SGC SUPERIOR GROUP OF COMPANIES
UNB UNION BANKSHARES INC.
CHMG CHEMUNG FINANCIAL CORP.
EIDX EIDOS THERAPEUTICS
UI UBIQUITI INC.
CMBM CAMBIUM NETWORKS
RAPT RAPT THERAPEUTICS
SPT SPROUT SOCIAL
CLPT INC.
CLEARPOINT NEURO
INC.
- Jonathan Moreland
HPP HUDSON PACIFIC PROPERTIES INC.
PAH PLATFORM SPECIALTY PRODUCTS
DLY LYONDELLBASELL INDUSTRIES NV
KAMN KAMAN CORPORATION CLASS A
IMGN IMMUNOGEN INC.
HTLF HEARTLAND FINANCIAL USA INC.
HCAP HARVEST CAPITAL CREDIT CORP
FB FACEBOOK INC. CLASS A
OVINTIV INC
DISH DISH NETWORK CORPORATION CLASS A
CODI COMPASS DIVERSIFIED HOLDINGS
BG BUNGE LIMITED
CBFV CB FINANCIAL SERVICES INC.
IO ION GEOPHYSICAL
JMP JMP GROUP LLC
HRTG HERITAGE INSURANCE HOLDINGS INC.
CSV CARRIAGE SERVICES INC.
NSA NATIONAL STORAGE AFFILIATES TRUST
ASIX ADVANSIX INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
PFIS PEOPLES FINANCIAL SERVICES CORP.
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Res...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018. “We have achieved a number of important milestones to start the year, led by the advancement of mirvetuximab soravtansine,” said Mark Enyedy, ImmunoGen’s president and chief executive officer. “Our FORWARD I registration trial continues as planne...
ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd ...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference. The presentation is scheduled for 8:40am ET on May 9, 2018. A webcast of the presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approxi...
ImmunoGen Announces Successful Completion of Interim Analysis for FORW...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification. The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) based upon successful completion of a pre-specified in...
ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief ...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee, Ph.D. has been appointed Executive Vice President and Chief Business Officer. “As ImmunoGen continues to evolve, we look to complement our existing team with outside talent with experience to accelerate our transition to a fully-integrated biotechnology company delivering innovative products to improve outcomes for cancer pat...
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 ...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 4, 2018 to discuss its first quarter operating results. Management also will provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 719-325-4799; the conference ID is 2070974. The call may also be accessed through the I...
ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Sor...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer (EOC). These data are being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting, March 24-27, 2018 ...
ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting ...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 14-18, 2018 in Chicago. “ImmunoGen has in-depth expertise in all aspects of ADCs, which has resulted in the most comprehensive toolbox of ADC technologies in the ...
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended December 31, 2017. “We made significant progress with the business in 2017, with four consecutive quarters of strong execution across the Company. Operationally, we advanced our monotherapy registration study and published compelling combination data with mirvetuximab, expand...
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Leerink Partners 7th Annual Global Healthcare ConferenceFebruary 15 at 3:30pm ET RBC Capital Markets 2018 Global Healthcare ConferenceFebruary 21 at 2:35pm ET Cowen and Company 38th Annual He...
ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Resu...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results. Management also will provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 719-325-4917; the conference ID is 5734226. The call may also be accessed through the Inves...
ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 fo...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been treated with IMGN632 in a Phase 1 clinical trial of patients with CD123-positive hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). IMGN632 uses ImmunoGen's novel indolino-benzodiazepine payload, DGN549, which alkylates DNA without crosslin...
ImmunoGen Announces Webcast of Presentation and Q&A at the 36th Annual...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:30am PT (11:30am ET) on January 10, 2018. Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at...
ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Mee...
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the Company’s ongoing Phase 1 study of IMGN779, a next-generation CD33-targeting ADC, in patients with relapsed or refractory adult acute myeloid leukemia (AML) were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Poster presentations on preclinical data for IMGN779 in combination with cytarabine ...
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Jefferies 2017 London Healthcare ConferenceNovember 15, 2017 at 10:40am GMT Evercore ISI Biopharma Catalyst/Deep Dive ConferenceNovember 30, 2017 at 3:30pm ET A webcast of each presentation ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.